The technological advancements in the last two decades have made significant changes in industries around the globe and the manufacturing industry is no exception to that. Numerous additive manufacturing technologies like 3D printing have grown rapidly over the past few years. Bioprinting is one of those extensions of traditional 3D printing that has taken the healthcare and personalized medical industry by a storm. The artificial creation of human skin, tissues, and internal organs may sound futuristic, but it has turned into reality by the bioprinting phenomenon. As this concept is gaining ground slowly, there are several companies and startups that are providing the bioprinting technology solutions presently.
Founded in 2007, regenHU was established to innovate and grow the technology of 3D bioprinting from its earliest days. It is a pioneer and global leader in tissue and organ printing technologies converging 3D printing, biomaterials, and biotechnology to lead transformational innovations in healthcare. regenHU has dedicated its engineering skills to assist the scientific community with its solutions.
Cutting-Edge 3D Bioprinting Solutions
regenHU designs, develops, and manufactures bioprinting instruments, bioprinting software and solutions for transformational innovation in tissue engineering, regenerative medicine and drug discovery. The company takes factors like precision and reproducibility into consideration while designing its solutions that complement today’s researchers and tomorrow’s industrial biofabrication needs. The 3D bioprinters manufactured by the company include 3DDiscovery™ Evolution and 3DDiscovery™ Evolution BioSafety. It also develops the most intuitive and advanced software tools.
The company personalizes each instrument to the specific project needs of its users, and provides multiple bioprinting technologies in one instrument. This enables true multi-material printing for its global customer portfolio comprising key players in biotech, pharma, cosmetics, and medtech industries in addition to leading universities around the world.
Stellar Client Base
Being a pioneer in the field, regenHU has worked with several clients over the years and has successfully managed the client satisfaction and retention. The stellar client base of regenHU comprises of renowned companies such as L’Oréal, The Jackson Laboratory, GSK, Novartis Pharmaceuticals, Coltene, etc. The company also serves leading universities such as The University of Nottingham, Technical University of Denmark, University of Zurich, University of Dublin, Oregon Health and Science University, and many more. Due to its precise solutions, the client base has grown extensively over the years and promises to continue to grow in the near future as well.
A Dedicated Leader with Avid Experience
Dr. Simon MacKenzie, the CEO of regenHU, is contributing highly towards the growth of the company. He has more than 15 years of experience of senior business and scientific roles in drug discovery, innovation, business development, and collaborative alliance management. He also has a successful track record of implementing strategic visions to create and grow scientific businesses and has knowledge of multiple cultural methodologies gained from working in pharma, biotech, academic, and service organizations in Japan, the US, and the UK.
With this avid experience in regenerative medicine and pharma, he could easily see the potential of bioprinting to revolutionize many areas of medical science, thus he decided to join regenHU. As the CEO, he provides the right support structure to enable its entrepreneurial engineering teams to thrive and be brave enough to push boundaries. Furthermore, he nurtures the important connections with regenHU’s user community. He thinks that the company can push the technology onwards only by listening to the customers’ valuable insights and solving problems with them.
Excelling the Challenges with a Driven Team
Like every company, regenHU also confronts numerous challenges. One of the major challenges in front of the company is the current limitations in the scale and volume of bioprinting which is linked to the reproducibility of the print. Thus, to progress into the manufacturing of medical products, bioprinters will need to operate at a scale beyond current capabilities. regenHU has designed its instruments with these goals in mind, and also has assembled a team to solve the challenges. The regenHU team is extremely motivated and driven. The team is given the freedom to develop technologies that they passionately believe will change the way companies finds medicines and treats diseases. This motivated and driven team has been instrumental in coping with the challenges confronting the company.
Impacts of the COVID-19 Pandemic
The outbreak of the COVID-19 pandemic is turning out to be one of the deadliest disease outbreaks in the recent past. Along with other industries, the manufacturing industry is one of the most affected industries due to the pandemic. It is reflecting in the bioprinting field as well. Bioprinting being still a young scientific field, research into all three necessary components, i.e. instruments, biomaterials, and cells is the key to progress. The inability to travel, and the cancellation or postponement of conferences to attend has reduced the ability of companies to meet and discuss solutions to problems. This is ultimately slowing the development of new technologies. regenHU is prepared to face these challenges with its future projects.
Advancements in Near Future
regenHU has been the pioneer in 3D bioprinting for many years. While working closely with the user community, the company has seen the limitations that are preventing it from reaching the commercial biofabrication of tissues and organs. regenHU is developing solutions to these problems and will bring these solutions to market in the near future. Organtrans, a European consortium that regenHU is a part of is a good example of the solution driven projects that the company is currently engaged in. By this, regenHU aspires to move the field closer to the potential of true regenerative medicine.
Future of 3D Bioprinting
Though 3D printing has grown rapidly over the past few years, it’s still a number of years behind mainstream 3D printing. Industrialization of the instruments, biomaterials, and cells is required for bioprinting to progress to commercial scale biofabrication. However, with continued developments in 3D printing, the technology convergence required for tissue and organ printing that changes medical treatments will become a reality. The efforts of engineering companies like regenHU, biomaterial developers, and human cell expansion technologies are contributing towards the future of 3D bioprinting.
Read full magazine : Mirror Review’s Top 3D Printing Companies 2020
